Listen in as our expert panel discusses which diabetes meds have cardiovascular (CV) benefits. We’ll review the evidence and discuss the pros and cons of SGLT2 inhibitors (dapagliflozin, empagliflozin, etc) and GLP-1 agonists (dulaglutide, semaglutide, etc) in patients with or at risk for CV disease.
Special Guests:
TRC Editorial Advisory Board Participant:
For the purposes of disclosure, Dr. Schumacher reports a relevant financial relationship [CGM for diabetes management] with Abbott (speakers bureau).
The other speakers have nothing to disclose. All relevant financial relationships have been mitigated.
This podcast is an excerpt from one of TRC’s monthly live CE webinars, the full webinar originally aired in February 2025.
TRC Healthcare offers CE credit for this podcast. Log in to your Pharmacist’s Letter, Pharmacy Technician’s Letter,or Prescriber Insights account and look for the title of this podcast in the list of available CE courses.
The clinical resources mentioned during the podcast are part of a subscription to Pharmacist’s Letter, Pharmacy Technician’s Letter, and Prescriber Insights:
If you’re not yet a subscriber, find out more about our product offerings at trchealthcare.com.
Follow, rate, and review this show in your favorite podcast app. Find the show on YouTube by searching for ‘TRC Healthcare’ or clicking here.
You can also reach out to provide feedback or make suggestions by emailing us at ContactUs@trchealthcare.com.